This clinical trial is focused on studying the treatment of Chronic Hepatitis B, a long-term infection of the liver caused by the hepatitis B virus. The study will use a medication called Bepirovirsen, which is administered as a solution for injection. Participants in the study will either receive Bepirovirsen or a placebo, which is a substance with no active medication.
The purpose of the study is to evaluate the effectiveness and safety of Bepirovirsen in achieving a functional cure for individuals with chronic hepatitis B who are already being treated with nucleos(t)ide analogues, a type of medication that helps control the virus. The study will last for 24 weeks, during which participants will receive Bepirovirsen with initial higher doses to help achieve the desired treatment effect.
Throughout the study, participants will be monitored to assess the impact of the treatment on their condition. The goal is to determine if Bepirovirsen can help achieve a functional cure, meaning the virus is controlled without the need for ongoing medication. This study is part of a larger effort to find effective treatments for chronic hepatitis B and improve the quality of life for those affected by this condition.
Bulgaria 
France 
Germany 
Greece 
Hungary 
Italy 
Poland 
Romania 
Spain